NCT05361668 2026-03-19
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Completed
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
National Institute of Cardiology, Warsaw, Poland
M.D. Anderson Cancer Center